Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Combining Cytotoxic and Targeted Therapies for Lung Cancer

Combining Cytotoxic and Targeted Therapies for Lung Cancer EDITORIAL Combining Cytotoxic and Targeted Therapies for Lung Cancer Matjaz Zwitter, MD, PhD n this issue, Heist et al. present experience from a phase I to II trial of a combination Iof topotecan and targeted drug AT-101 for patients with small cell lung cancer in progression after first-line chemotherapy. Although the trial did not include a control group and the study population was relatively small, it nevertheless seems that this combination of a targeted drug and chemotherapy is not superior to chemotherapy alone. A similar conclusion may be derived from five other studies on advanced non-small cell lung cancer with a total of more than 5000 patients. Two trials (INTACT 1 and 2,3 INTACT 2) tested chemotherapy alone or in combination with gefitinib and the other 4,5 two (TRIBUTE and TALENT) tested chemotherapy with or without erlotinib. In all four trials, adding a tyrosine kinase inhibitor to chemotherapy did not prolong the time to progression or overall survival. The fifth study is the recently published FLEX trial in which chemotherapy was given with or without cetuximab. Addition of cetuximab led to moderate yet statistically significant prolongation of overall survival. However, there was an important difference in the duration of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Combining Cytotoxic and Targeted Therapies for Lung Cancer

Zwitter, Matjaz
Journal of Thoracic Oncology , Volume 5 (10) – Oct 1, 2010
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/combining-cytotoxic-and-targeted-therapies-for-lung-cancer-1q3EZnmS4Y

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181e7d04e
pmid
20871258
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Combining Cytotoxic and Targeted Therapies for Lung Cancer Matjaz Zwitter, MD, PhD n this issue, Heist et al. present experience from a phase I to II trial of a combination Iof topotecan and targeted drug AT-101 for patients with small cell lung cancer in progression after first-line chemotherapy. Although the trial did not include a control group and the study population was relatively small, it nevertheless seems that this combination of a targeted drug and chemotherapy is not superior to chemotherapy alone. A similar conclusion may be derived from five other studies on advanced non-small cell lung cancer with a total of more than 5000 patients. Two trials (INTACT 1 and 2,3 INTACT 2) tested chemotherapy alone or in combination with gefitinib and the other 4,5 two (TRIBUTE and TALENT) tested chemotherapy with or without erlotinib. In all four trials, adding a tyrosine kinase inhibitor to chemotherapy did not prolong the time to progression or overall survival. The fifth study is the recently published FLEX trial in which chemotherapy was given with or without cetuximab. Addition of cetuximab led to moderate yet statistically significant prolongation of overall survival. However, there was an important difference in the duration of

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Oct 1, 2010

References

  • Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer (SCLC)
    Heist
  • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1
    Giaccone
  • Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2
    Herbst
  • TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Herbst
  • Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
    Gatzemeier
  • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    Pirker
  • Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial
    Brodowicz
  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
    Ciuleanu
  • Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm
    Mok
  • Repopulation of tumour cells between cycles of chemotherapy: a neglected factor
    Davis
  • Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation
    Mahaffey
  • Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells
    Li
  • Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel
    Solit
  • Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
    Davies
  • Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
    Mok